Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00396344 · ClinicalTrials.gov registry record · NA
Cortisol Control of Human Inflammatory Responses to Endotoxin
A NA study, sponsored by Dartmouth-Hitchcock Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 36
- Enrollment target
NCT00396344 is a NA study that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 36 participants.
The verdict
NCT00396344, a NA study, has completed, sponsored by Dartmouth-Hitchcock Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purpose of the research is to study a common and dangerous medical condition called 'septic shock' that often occurs in critically ill patients. In order to learn about septic shock in humans, we will administer a substance called 'endotoxin' to participants in this study. Endotoxin causes a temporary period of inflammation in the human body, a brief 'virtual' infection. This is an established method for the investigation of inflammation properties. We are interested in how the natural hormone, cortisol, can affect the human response to endotoxin. We know that when cortisol is given at the same time as endotoxin it can decrease the inflammation that occurs due to endotoxin. In this study we will test whether or not cortisol, when given the day before the endotoxin, will work to change the inflammation that occurs due to endotoxin. In order to test this, two-thirds of the study participants will receive cortisol on the day before they receive the endotoxin and one-third of the study participants will receive a placebo (no medication) before the endotoxin.
Interventions
- DRUG Hydrocortisone
- OTHER Çontrol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2006-10 |
| Est. Completion | 2007-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00396344
The ClinicalTrials.gov registry entry for NCT00396344 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dartmouth-Hitchcock Medical Center, which has 427 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Hydrocortisone is the first listed.
NCT00396344 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00396344 about?
NCT00396344 is a clinical study titled "Cortisol Control of Human Inflammatory Responses to Endotoxin". The purpose of the research is to study a common and dangerous medical condition called 'septic shock' that often occurs in critically ill patients. In order to learn about septic shock in humans, we will administer a substance called 'endotoxin' to participants in this study. Endotoxin causes a tem...
What is the current status of trial NCT00396344?
This trial is currently completed. It is a NA study. The enrollment target is 36 participants. The study started on 2006-10. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00396344?
The interventions under investigation include: Hydrocortisone (DRUG), Çontrol (OTHER).
Who is sponsoring clinical trial NCT00396344?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.